4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
6.96
+0.29 (4.35%)
Aug 14, 2025, 11:39 AM - Market open
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover 4D Molecular Therapeutics stock have a consensus rating of "Buy" and an average price target of $30.63, which forecasts a 340.09% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $40.
Price Target: $30.63 (+340.09%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth Capital | Roth Capital | Strong Buy Maintains $44 → $38 | Strong Buy | Maintains | $44 → $38 | +445.98% | Aug 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +259.20% | Aug 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +259.20% | Aug 1, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +259.20% | Jul 3, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $28 → $25 | Strong Buy | Maintains | $28 → $25 | +259.20% | May 9, 2025 |
Financial Forecast
Revenue This Year
4.32M
from 37.00K
Increased by 11,586.49%
Revenue Next Year
3.20M
from 4.32M
Decreased by -25.95%
EPS This Year
-3.63
from -2.98
EPS Next Year
-3.92
from -3.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 21.0M | 21.0M | ||
| Avg | 4.3M | 3.2M | 4.0M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 56,656.8% | 385.7% | 555.8% | ||
| Avg | 11,586.5% | -25.9% | 25.1% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.22 | -2.94 | -1.64 | ||
| Avg | -3.63 | -3.92 | -4.02 | ||
| Low | -3.98 | -5.04 | -6.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.